HER2-positive metastatic breast cancer; HER2-negative breast cancer Archives

The FDA Approves Tukysa™ for Metastatic HER2-Positive Breast Cancer

Post author:Rose Duesterwald
Post published:April 22, 2020
Post category:Breast Cancer Rare Disease

Seattle Genetics, Bothell, Washington recently issued an announcement through Drugs.com that the FDA approved Tukysa™ combined with capecitabine and trastuzumab for patients with metastatic HER2-positive breast cancer. The drug combination…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

The FDA Approves Tukysa™ for Metastatic HER2-Positive Breast Cancer

The Let’s Chat CAR T One-on-One Mentor Program: Speaking with Someone Who Understands What You Are Going Through

“Shades of Psoriasis”: Plaque Psoriasis and Sharing Your Story

Understanding RSV: Why Combatting Ethnic and Age-Related Health Disparities Could Improve Outcomes

We Need Equity and Diversity Within Rare Disease Research

DNA in Color: How Ronya Nelson is Working to Close the Diversity Gap in Genetics - Part 1

Bridging the Diversity Gap in Healthcare

Congratulations to the 2023 Recipients of the Diversity in Lupus Research Awards!

Welcome to Study of the Week. We go in-depth and select a study we think is of particular interest, discussing details, explaining its importance, who may be impacted and lots more!

Let’s Work Together!

Keep Up to Date

Learn More